Comparative outcomes of direct-acting antiviral treatment in patients with HIV-Hepatitis C co-infection: insights from a single center experience in Colombia.

Q2 Medicine Infezioni in Medicina Pub Date : 2023-01-01 DOI:10.53854/liim-3103-11

Hernán Vergara-Samur, Samuel Martínez-Vernaza, Alejandro De la Hoz, Julián Barahona-Correa, Juan Pablo Ortiz, Sandra Gualtero-Trujillo, José Rumbo-Romero, Luis Miguel Salazar, Yanette Suárez Quintero, Sandra Valderrama-Beltrán

{"title":"Comparative outcomes of direct-acting antiviral treatment in patients with HIV-Hepatitis C co-infection: insights from a single center experience in Colombia.","authors":"Hernán Vergara-Samur, Samuel Martínez-Vernaza, Alejandro De la Hoz, Julián Barahona-Correa, Juan Pablo Ortiz, Sandra Gualtero-Trujillo, José Rumbo-Romero, Luis Miguel Salazar, Yanette Suárez Quintero, Sandra Valderrama-Beltrán","doi":"10.53854/liim-3103-11","DOIUrl":null,"url":null,"abstract":"Background: Direct-acting antivirals (DAA) were introduced to Latin America with the aim of eliminating hepatitis C (HCV) in the region. There are scarce data on the outcomes of people living with HIV and HCV treated with these medications in Colombia. This study compares the outcomes of patients with HIV-HCV co-infection and HCV mono-infection treated with DAAs.Methods: Retrospective observational study including patients ≥18 years old with HCV infection treated with DAAs from August 2017 to December 2019 in a comprehensive center in Colombia. The main outcome was sustained virologic response (SVR). Secondary outcomes included reinfection, relapse and adverse events.Results: We included 223 individuals with HCV treated with DAAs; 142 (63.6%) individuals were mono-infected and 81 (36.3%) co-infected. Genotypes 1b (49.7%) and 4 (33.9%) were the most common. Overall SVR after DAA treatment was 96.8%. Relapse rate was 2.24%, reinfection rate was 6.28% and adverse events occurred in 27.8% of cases. SVR was comparable in patients with co- and mono-infection (95% vs 97.8%, p=0.245).Conclusion: DAA were effective in mono-infected (HCV) and co-infected (HCV/HIV) patients and reinfection was high in this last group.","PeriodicalId":52423,"journal":{"name":"Infezioni in Medicina","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495049/pdf/1124-9390_31_3_2023_374-383.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infezioni in Medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53854/liim-3103-11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Direct-acting antivirals (DAA) were introduced to Latin America with the aim of eliminating hepatitis C (HCV) in the region. There are scarce data on the outcomes of people living with HIV and HCV treated with these medications in Colombia. This study compares the outcomes of patients with HIV-HCV co-infection and HCV mono-infection treated with DAAs.

Methods: Retrospective observational study including patients ≥18 years old with HCV infection treated with DAAs from August 2017 to December 2019 in a comprehensive center in Colombia. The main outcome was sustained virologic response (SVR). Secondary outcomes included reinfection, relapse and adverse events.

Results: We included 223 individuals with HCV treated with DAAs; 142 (63.6%) individuals were mono-infected and 81 (36.3%) co-infected. Genotypes 1b (49.7%) and 4 (33.9%) were the most common. Overall SVR after DAA treatment was 96.8%. Relapse rate was 2.24%, reinfection rate was 6.28% and adverse events occurred in 27.8% of cases. SVR was comparable in patients with co- and mono-infection (95% vs 97.8%, p=0.245).

Conclusion: DAA were effective in mono-infected (HCV) and co-infected (HCV/HIV) patients and reinfection was high in this last group.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

hiv -丙型肝炎合并感染患者直接抗病毒治疗的比较结果:来自哥伦比亚单一中心经验的见解

背景:直接作用抗病毒药物(DAA)被引入拉丁美洲，目的是消除该地区的丙型肝炎(HCV)。关于哥伦比亚艾滋病毒和丙型肝炎病毒感染者接受这些药物治疗的结果的数据很少。这项研究比较了HIV-HCV合并感染和HCV单一感染患者接受DAAs治疗的结果。方法:回顾性观察研究，纳入2017年8月至2019年12月在哥伦比亚某综合中心接受DAAs治疗的≥18岁HCV感染患者。主要结果为持续病毒学应答(SVR)。次要结局包括再感染、复发和不良事件。结果:我们纳入了223例接受DAAs治疗的HCV患者;单独感染142例(63.6%)，合并感染81例(36.3%)。基因型1b(49.7%)和基因型4(33.9%)最为常见。DAA治疗后的总SVR为96.8%。复发率为2.24%，再感染率为6.28%，不良事件发生率为27.8%。合并感染和单一感染患者的SVR相当(95% vs 97.8%， p=0.245)。结论:DAA对单一感染(HCV)和合并感染(HCV/HIV)患者均有效，且合并感染患者的再感染率较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Infezioni in Medicina Medicine-Infectious Diseases

CiteScore

8.40

自引率

0.00%

发文量

期刊介绍： The Journal publishes original papers, in Italian or in English, on topics concerning aetiopathogenesis, prevention, epidemiology, diagnosis, clinical features and therapy of infections, whose acceptance is subject to the referee’s assessment. The Journal is of interest not only to infectious disease specialists, microbiologists and pharmacologists, but also to internal medicine specialists, paediatricians, pneumologists, and to surgeons as well. The Editorial Board includes experts in each of the above mentioned fields.